Chinese Medical E-ournals Database
Adv Search
中华妇幼临床医学杂志(电子版)

Chinese Journal of Obstetrics & Gynecology and Pediatrics(Electronic Edition) ›› 2020, Vol. 16 ›› Issue (02): 150 -154. doi: 10.3877/cma.j.issn.1673-5250.2020.02.005

Special Issue: ；

Editorial

Research status of fertility preservation strategies in breast cancer patients

Yimei Wu1, Li Jin1, Hefeng Huang1,†()   

  1. 1. International Peace Maternity and Child Health Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai 200030, China
  • Received:2020-01-05 Revised:2020-03-20 Published:2020-04-01
  • Corresponding author: Hefeng Huang
  • About author:
    Corresponding author: Huang Hefeng, Email:
  • Supported by:
    National Natural Science Foundation of China(81871140)
HTML ( ) PDF ( )

Breast cancer is the most common female malignant tumor in China. Thanks to the continuous development of breast cancer diagnosis and treatments strategies, the overall survival rate and disease-free survival rate have been greatly improved. The fertility demand of breast cancer patients of childbearing age has also received increasing attention. However, the anticancer treatments of breast cancer, such as chemotherapy, radiotherapy, and endocrine therapy, may impair gonadal function and lead to infertility of breast cancer patients. This article outlines current treatments strategies for fertility preservation of breast cancer patients, including the well-established methods such as embryo cryopreservation and oocyte cryopreservation, and the potential alternatives such as ovarian tissue cryopreservation and in vitro maturation (IVM) technique. The application of gonadotropin-releasing hormone agonists (GnRHa) to protect the ovary during chemotherapy is still under controversial. Breast cancer patients can choose the right time to try pregnancy after treatment, and pregnancy does not increase the recurrence rate and mortality of breast cancer patients. This article intends to elaborate on the latest research progresses on the impact of breast cancer treatment on fertility, fertility preservation strategies, timing and safety of pregnancy, and aims to provide references for fertility preservation of breast cancer patients.

Key words: Ovarian neoplasms, Preconception injuries, Fertility preservation, Embryo and oocyte cryopreservation, Ovarian tissue cryopreservation, In vitro maturation of oocyte, Infertility, Female
[1]
Chen W, Zheng R, Baade PD, et al. Cancer statistics in China, 2015 [J]. CA Cancer J Clin, 2016, 66(2): 115-132. DOI: 10.3322/caac.21338.
[2]
Hassan Zafar MS, Khan AA, Aggarwal S, et al. Efficacy and tolerability of bortezomib and dexamethasone in newly diagnosed multiple myeloma [J]. South Asian J Cancer, 2018, 7(1): 58-60. DOI: 10.4103/sajc.sajc_59_17.
[3]
Puttabyatappa M, Padmanabhan V. Developmental programming of ovarian functions and dysfunctions [J]. Vitam Horm, 2018, 107: 377-422. DOI: 10.1016/bs.vh.2018.01.017.
[4]
Marci R, Mallozzi M, Di Benedetto L, et al. Radiations and female fertility [J]. Reprod Biol Endocrinol, 2018, 16(1): 112. DOI: 10.1186/s12958-018-0432-0.
[5]
Griffiths MJ, Winship AL, Hutt KJ. Do cancer therapies damage the uterus and compromise fertility? [J]. Hum Reprod Update, 2020, 26(2): 161-173. DOI: 10.1093/humupd/dmz041.
[6]
Bajpai J, Majumdar A, Satwik R, et al. Practical consensus recommendations on fertility preservation in patients with breast cancer [J]. South Asian J Cancer, 2018, 7(2): 110-114. DOI: 10.4103/sajc.sajc_113_18.
[7]
Munster PN. Effect of temporary ovarian suppression on chemotherapy-induced amenorrhea, pregnancy, and outcome [J]. JAMA Oncol, 2016, 2(8): 1089-1090. DOI: 10.1001/jamaoncol.2016.0614.
[8]
Roness H, Kashi O, Meirow D. Prevention of chemotherapy-induced ovarian damage [J]. Fertil Steril, 2016, 105(1): 20-29. DOI: 10.1016/j.fertnstert.2015.11.043.
[9]
Spears N, Lopes F, Stefansdottir A, et al. Ovarian damage from chemotherapy and current approaches to its protection [J]. Hum Reprod Update, 2019, 25(6): 673-693. DOI: 10.1093/humupd/dmz027.
[10]
Lambertini M, Ceppi M, Cognetti F, et al. Dose-dense adjuvant chemotherapy in premenopausal breast cancer patients: a pooled analysis of the MIG1 and GIM2 phase Ⅲ studies [J]. Eur J Cancer, 2017, 71: 34-42. DOI: 10.1016/j.ejca.2016.10.030.
[11]
Lambertini M, Del Mastro L, Pescio MC, et al. Cancer and fertility preservation: international recommendations from an expert meeting [J]. BMC Med, 2016, 14(1): 1. DOI: 10.1186/s12916-015-0545-7.
[12]
Jyoti B, Bharat C, Ankita N, et al. Pregnancy on tamoxifen: case-report and review of literature [J]. South Asian J Cancer, 2016, 5(4): 209-210. DOI: 10.4103/2278-330X.195347.
[13]
Torino F, Barnabei A, De Vecchis L, et al. Chemotherapy-induced ovarian toxicity in patients affected by endocrine-responsive early breast cancer [J]. Crit Rev Oncol Hematol, 2014, 89(1): 27-42. DOI: 10.1016/j.critrevonc.2013.07.007.
[14]
Oktay K, Harvey BE, Partridge AH, et al. Fertility preservation in patients with cancer: ASCO clinical practice guideline update [J]. J Clin Oncol, 2018, 36(19): 1994-2001. DOI: 10.1200/JCO.2018.78.1914.
[15]
Rodgers RJ, Reid GD, Koch J, et al. The safety and efficacy of controlled ovarian hyperstimulation for fertility preservation in women with early breast cancer: a systematic review [J]. Hum Reprod, 2017, 32(5): 1033-1045. DOI: 10.1093/humrep/dex027.
[16]
Letourneau JM, Wald K, Sinha N, et al. Fertility preservation before breast cancer treatment appears unlikely to affect disease-free survival at a median follow-up of 43 months after fertility-preservation consultation [J]. Cancer, 2020, 126(3): 487-495. DOI: 10.1002/cncr.32546.
[17]
Sonigo C, Sermondade N, Calvo J, et al. Impact of letrozole supplementation during ovarian stimulation for fertility preservation in breast cancer patients [J]. Eur J Obstet Gynecol Reprod Biol X, 2019, 4: 100049. DOI: 10.1016/j.eurox.2019.100049.
[18]
Quinn MM, Cakmak H, Letourneau JM, et al. Response to ovarian stimulation is not impacted by a breast cancer diagnosis [J]. Hum Reprod, 2017, 32(3): 568-574. DOI: 10.1093/humrep/dew355.
[19]
Taylan E, Oktay KH. Current state and controversies in fertility preservation in women with breast cancer [J]. World J Clin Oncol, 2017, 8(3): 241-248. DOI: 10.5306/wjco.v8.i3.241.
[20]
Doyle JO, Richter KS, Lim J, et al. Successful elective and medically indicated oocyte vitrification and warming for autologous in vitro fertilization, with predicted birth probabilities for fertility preservation according to number of cryopreserved cocytes and age at retrieval [J]. Fertil Steril, 2016, 105(2): 459-466.e2. DOI: 10.1016/j.fertnstert.2015.10.026.
[21]
Grynberg M, Poulain M, Le Parco S, et al. Similar in vitro maturation rates of oocytes retrieved during the follicular or luteal phase offer flexible options for urgent fertility preservation in breast cancer patients [J]. Hum Reprod, 2016, 31(3): 623-629. DOI: 10.1093/humrep/dev325.
[22]
Shirasawa H, Terada Y. In vitro maturation of human immature oocytes for fertility preservation and research material [J]. Reprod Med Biol, 2017, 16(3): 258-267. DOI: 10.1002/rmb2.12042.
[23]
Applications P, Ivm OF. In vitro maturation: a committee opinion [J]. Fertil Steril, 2013, 99(3): 663-666. DOI: 10.1016/j.fertnstert.2012.12.031.
[24]
Batchvarov IS, Taylor RW, Bustamante-Marin X, et al. A grafted ovarian fragment rescues host fertility after chemotherapy [J]. Mol Hum Reprod, 2016, 22(12): 842-851. DOI: 10.1093/molehr/gaw064.
[25]
Ruan X, Du J, Korell M, et al. Case report of the first successful cryopreserved ovarian tissue retransplantation in China [J]. Climacteric, 2018, 21(6): 613-616. DOI: 10.1080/13697137.2018.1514005.
[26]
Bastings L, Beerendonk CCM, Westphal JR, et al. Autotransplantation of cryopreserved ovarian tissue in cancer survivors and the risk of reintroducing malignancy: a systematic review [J]. Hum Reprod Update, 2013, 19(5): 483-506. DOI: 10.1093/humupd/dmt020.
[27]
Munhoz RR, Pereira AAL, Sasse AD, et al. Gonadotropin-releasing hormone agonists for ovarian function preservation in premenopausal women undergoing chemotherapy for early-stage breast cancer: a systematic review and Meta-analysis[J]. JAMA Oncol, 2016, 2(1): 65-73. DOI: 10.1001/jamaoncol.2015.3251.
[28]
Zheng F, Zhu B, Feng Q, et al. Protective effect of gonadotropinreleasing hormone agonist against chemotherapyinduced ovarian dysfunction: a Meta-analysis [J]. Oncol Lett, 2019, 17(6): 5319-5326. DOI: 10.3892/ol.2019.10252.
[29]
Martinez F, International Society for Fertility Preservation-ESHRE-ASRM Expert Working Group. Update on fertility preservation from the Barcelona International Society for Fertility Preservation-ESHRE-ASRM 2015 expert meeting: indications, results and future perspectives [J]. Hum Reprod, 2017, 108(3): 407-415.e11. DOI: 10.1016/j.fertnstert.2017.05.024.
[30]
Coates AS, Winer EP, Goldhirsch A, et al. Tailoring therapies-improving the management of early breast cancer: St Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2015 [J]. Ann Oncol, 2015, 26(8): 1533-1546. DOI: 10.1093/annonc/mdv221.
[31]
Carneiro MM, Cota AM, Amaral MC, et al. Motherhood after breast cancer: can we balance fertility preservation and cancer treatment? A narrative review of the literature [J]. JBRA, 2018, 22(3): 244-252. DOI: 10.5935/1518-0557.20180032.
[32]
中国抗癌协会乳腺癌专业委员会. 中国抗癌协会乳腺癌诊治指南与规范(2019年版)[J]. 中国癌症杂志，2019, 29(8): 609-680. DOI: 10.19401/j.cnki.1007-3639.2019.08.009.
[1] Jinping Wang, Jiajia Wang, Yan Li, Qin Wang, Jing Zhang, Xiaoyi Chen, Xin Lin. Preliminary application of a new cone-head uterine tube in hysterosalping constrast sonography[J]. Chinese Journal of Medical Ultrasound (Electronic Edition), 2023, 20(03): 272-277.
[2] Minrong Ma, Cong Li, Qin Zhou. Current research status of treatment of cervical cancer[J]. Chinese Journal of Obstetrics & Gynecology and Pediatrics(Electronic Edition), 2023, 19(05): 497-504.
[3] Changsheng Lin, Jun Zhan, Xue Xiao. Genetic testing and precision molecular targeted therapy in diagnosis and treatment of epithelial ovarian caner[J]. Chinese Journal of Obstetrics & Gynecology and Pediatrics(Electronic Edition), 2023, 19(05): 505-510.
[4] Juan Gu, Qingqing Sun, Fangfang Hu, Yijuan Cao, Yujuan Qi. Clinical application of endometrial receptivity array to improve pregnancy outcomes in women with repeated embryo implantation failure[J]. Chinese Journal of Obstetrics & Gynecology and Pediatrics(Electronic Edition), 2023, 19(05): 582-587.
[5] Wenrong Dai, Lijuan Zhao, Zhihui Li. Research progress of influence of extracellular vesicles on embryo implantation[J]. Chinese Journal of Obstetrics & Gynecology and Pediatrics(Electronic Edition), 2023, 19(05): 616-620.
[6] Dongjie Zhou, Min Jiang, Hairui Fan, Lingling Gao, Xiang Kong, Dan Lu, Liping Wang. Current research progress on non-coding RNA in follicular development and maturation[J]. Chinese Journal of Obstetrics & Gynecology and Pediatrics(Electronic Edition), 2023, 19(04): 387-393.
[7] Huizhu Chen, Yingkun Guo, Xinrong Wang, Gang Ning, Xijian Chen. Current research status on the " dualistic model" of epithelial ovarian cancer and its molecular biology[J]. Chinese Journal of Obstetrics & Gynecology and Pediatrics(Electronic Edition), 2023, 19(04): 394-402.
[8] Chunying Han, Tingting Wang, Yanyan Li, Jinxia Piao. Current research status on predictors of lymphatic vascular invasion in patients with endometrial carcinoma[J]. Chinese Journal of Obstetrics & Gynecology and Pediatrics(Electronic Edition), 2023, 19(04): 403-409.
[9] Xingchen Liu, Juan Liu, Baobao Wei, Jie Liu, Hui Liu. Correlation analysis of abnormal expression of XIAP and XAF1 with ovarian cancer[J]. Chinese Journal of Obstetrics & Gynecology and Pediatrics(Electronic Edition), 2023, 19(04): 419-427.
[10] Zhaomin Zeng, Haiyan Yu. Clinical cognition of superfemale syndrome[J]. Chinese Journal of Obstetrics & Gynecology and Pediatrics(Electronic Edition), 2023, 19(02): 145-150.
[11] Quan Wei, Shen Zhang, Huijia Chen, Heng Zou, Lina Hu. Current research progress on correlation between female reproductive tract microbiota and assisted reproductive technology[J]. Chinese Journal of Obstetrics & Gynecology and Pediatrics(Electronic Edition), 2023, 19(02): 151-155.
[12] Yanyan Liu, Xi Tan, Xue Peng. Pregnancy complicated with papillary urothelial neoplasms of low malignant potential: a case report and literature review[J]. Chinese Journal of Obstetrics & Gynecology and Pediatrics(Electronic Edition), 2023, 19(02): 212-218.
[13] Xiaoli Wang, Qi Li, Chunfeng Li, Jingqi Wang, Xiaodong Guan. Effect of laparoscopic high ligation of internal spermatic vein with testicular artery preservation on infertility caused by varicocele[J]. Chinese Journal of Endourology(Electronic Edition), 2023, 17(03): 261-264.
[14] Yu Zhang, Jie Miao. A review of the hysterosalpingography in the diagnosis of hydrosalpinx[J]. Chinese Journal of Interventional Radiology(Electronic Edition), 2023, 11(04): 336-340.
[15] Yuxin Liu, Zihan Wang, Yixin Zhang, Yongjie Luan, Kai Meng. Research progress of Wilms' tumor gene 1 in the pathogenesis of ovarian diseases[J]. Chinese Journal of Diagnostics(Electronic Edition), 2023, 11(03): 178-183.
Viewed
Full text


Abstract

Copyright © Chinese Medical Association, Chinese Medical Multimedia Press  京ICP备14006079号-1  网络出版服务许可证：(署)网出证(京)字第075号